Neuron23

South San Francisco, CA · Founded 2018 · Privately Held (backing)

Developer of an artificial intelligence-based drug discovery model designed for genetically defined neurological and immunological diseases. Neuron23 is based in South San Francisco, CA and was founded in 2018. Its last reported valuation was $272 million in Jun 2025. It has raised $310 million.

Last reported valuation
$271.5M
Oct 2026
Priced at
—
Total raised
$310.0M
Last round
—

Who backs Neuron23?

14 investors
InvestorType
SoftBank Investment AdvisersGrowth equity
Kleiner PerkinsOther
Blue Owl Capital—
Perceptive AdvisorsHedge fund
Chimera CapitalAsset manager
HBM PartnersVenture capital
Redmile GroupPE / buyout
Surveyor CapitalHedge fund
Citadel Enterprise AmericasHedge fund
Acorn BioventuresVenture capital
+ 4 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Neuron23 investors

14 investors are on record for Neuron23, including SoftBank Investment Advisers, Kleiner Perkins, Blue Owl Capital and Perceptive Advisors. By type, the record holds 3 hedge funds and 2 venture capital firms.

Free account
More of Neuron23 with a free account
  • ·The complete investor list: 14 names
  • ·Watch Neuron23: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 14 firms already write checks for companies like Neuron23. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View